stackBETA

Daily

  • Log

Verify

  • Cabinet · stacks
  • Vials · inventory

Build

  • Reconstitution

Plan

  • Can I get it?
  • Compare
  • Synergy check

Learn

  • Encyclopedia
  • Common stacks
  • Pulse
  • Methodology

Info

  • Partners & programs

Stack · v0.1 beta

stackBETAv0.1
LogEncyclopediaPulse
MethodologyPartners & programs
← Back to your stack
Monograph
FDA CAT. 1T-004
Longevity

NAD+ injectable / IV

Direct administration of NAD+ (rather than its precursors NMN or NR). IV infusion or subcutaneous injection bypasses the salvage-pathway conversion needed for oral precursors. The longevity-clinic standard for 'rapid NAD+ pool restoration.'

ExperimentalLongevity
Typical dose250-1000 mg per infusion
Frequencyweekly to monthly, IV or SC
Half-life2h
Citations indexed22
100%50%0%02h4h6h8h10ht½ 2hPK · plasma

How it clearsHalf cleared in ~2h. Most (~96%) gone by ~10h.

DeliveryInjectable
Half-life~2h
EvidenceExperimental
Citations22
Similar compounds
Stack Pro · compare side-by-side

Compare these compounds

Mechanism, evidence, legal path, cost — all side-by-side.

→
Synergy checkCompareReconstitution calc
Experimental

Evidence is experimental. Most claims trace to limited human studies or animal models. Treat as a research direction, not a protocol.

Mechanism

Marek Health, Ways2Well, Cenegenics, and most longevity-clinic chains offer IV NAD+ protocols (typically 250-1000 mg over 2-4 hours, weekly or monthly). The pharmacokinetic question — whether IV NAD+ raises intracellular NAD+ pools meaningfully more than oral precursors — has limited published data. Grant et al 2019 (small N) showed IV NAD+ achievable plasma rise but intracellular conversion remains the bottleneck. Most clinics market this on subjective energy/cognition outcomes, which lack RCT-grade validation.

Specifics
Cellular aging concernsLow energy / fatigueMitochondrial energy declineBrain fog
Caveats

Pharmacokinetic justification for IV NAD+ over cheaper oral NR/NMN is contested in academic literature. Infusion experience is unpleasant (chest pressure, flushing, headache during drip — slows infusion rate but doesn't eliminate). Cost-per-mg is dramatically higher than oral precursors. 503A compounding pharmacy quality varies — verify PCAB / NABP accreditation.

Evidence levelExperimental
Regulatory status503A compounded by longevity clinics · no FDA approval · widely offered at $200-$800 per infusion
DNA / pharmacogenomicsLow — NAMPT / CD38 polymorphisms theoretically modulate; PG not actionable.
Your data · empty

Upload your data to see how it relates to NAD+ IV.

Upload a lab file (LabCorp / Quest) or DNA file (23andMe / AncestryDNA). Stack will show your specific markers alongside the literature-reported response windows.

Upload in /history→
Claims & evidence

Per-claim grading. Each claim is graded independently — same peptide, different claims can carry different grades.

  • CLimited evidence

    Raises plasma NAD+ levels more rapidly than oral NR/NMN.

    1 supporting referencesVerified today
  • DMechanistic / anecdotal

    Produces clinically meaningful improvement in subjective energy + cognition in healthy adults.

    0 supporting referencesVerified today
References

External links to PubMed searches, ClinicalTrials.gov, and FDA materials. We do not host papers — we point at canonical sources.

  • PubMedEN
    RCTAcademic-funded
    Grant R et al, Front Aging Neurosci 2019 — IV NAD+ in healthy adults
  • ReviewEN
    Funding undisclosed
    PubMed — IV NAD+ longevity clinic review
FDA CAT. 1T-004

503A compounded by longevity clinics · no FDA approval · widely offered at $200-$800 per infusion

Can I get it? →
Reconstitution calculatorNAD+ IV

Pre-filled with this compound's published dose range: 250-1000 mg per infusion · weekly to monthly, IV or SC

Concentration2.50 mg/mL
Draw volume250.000 mL
Insulin syringe25000.0 u
Doses per vial0
U-100 syringe — fill to indicatorU-100 · 1 mL
0u25u50u75u100u
Watch

Draw volume exceeds 100 units (1 mL). Either reduce dose or split into multiple injections.

Calculator is a discussion tool. Verify reconstitution + dosing with a qualified provider. Stack is not a prescription source. Use sterile technique and inspect every vial.

No field reports yet

Field reports are added as users share their real-world protocols.

NAD+ IV250-1000 mg per infusion · weekly to monthly, IV or SC

Next visit & citations

Handoff & sources

Running this compound? Log it in /history, then open Dr Passport before your visit. Methodology explains grades; the research dashboard sorts the full catalog with citations.

Open Dr PassportMethodologyResearch tableClinician primer
Discussion guide, not prescription

stack is an exploration engine. Output is a discussion guide for a conversation with a licensed provider — never a prescription, dose recommendation, or sourcing instruction. Peptides discussed include compounds with limited human evidence and varying legal status by jurisdiction. Verify everything with a qualified clinician before any decision.

Full terms →
stackv0.1
AudiencesPartners & programsWho Stack is forFor creatorsFor researchersFor pharmaciesFor cliniciansFor press
Trust & regulatoryCalibrationMethodologyFDA statusPharmacy registryPCAC commentMX · COFEPRIS
Built honest. Bilingual from day one.
TodayLibrary
ToolsMe